We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0M8I market cap is 37.24M. The company's latest EPS is RON 0.0754 and P/E is 5.17.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| RON (RON) | RON (RON) | RON (RON) | RON (RON) | RON (RON) | |
| Total Revenue | 459.41M | 451.77M | 486.18M | 547.71M | 609.29M |
| Operating Income | 3.8M | 3.37M | 8.7M | 6.48M | 8.58M |
| Net Income | 2.44M | 37.77M | 7.23M | 5.81M | 7.2M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| RON (RON) | RON (RON) | RON (RON) | RON (RON) | RON (RON) | |
| Total Assets | 260.37M | 244.46M | 251.07M | 286.21M | 315.76M |
| Total Liabilities | 211.31M | 164.63M | 182.85M | 217.77M | 244.9M |
| Total Equity | 49.06M | 79.83M | 68.22M | 68.43M | 70.86M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| RON (RON) | RON (RON) | RON (RON) | RON (RON) | RON (RON) | |
| Operating | 4.85M | -13.52M | 2.63M | -1.99M | 23.22M |
| Investing | 3.13M | 39.89M | 583k | 239k | -969k |
| Financing | -1.23M | -2.29M | -13.35M | -4.53M | -5.7M |
| Market Cap | 37.24M |
| Price to Earnings Ratio | 5.17 |
| Price to Sales Ratio | 0.06 |
| Price to Cash Ratio | 1.08 |
| Price to Book Ratio | 0.53 |
| Dividend Yield | - |
| Shares Outstanding | 95.48M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Farmaceutica Remedia Sa |
| Address |
no. 2 nicolae balcescu bld deva 041836 |
| Website | https://www.remedia.ro |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
